Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
INO's Cash to Debt is ranked higher than
89% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. INO: No Debt )
INO' s 10-Year Cash to Debt Range
Min: 0.97   Max: No Debt
Current: No Debt

Equity to Asset 0.87
INO's Equity to Asset is ranked higher than
88% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INO: 0.87 )
INO' s 10-Year Equity to Asset Range
Min: 0.44   Max: 0.95
Current: 0.87

0.44
0.95
Interest Coverage No Debt
INO's Interest Coverage is ranked higher than
87% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INO: No Debt )
INO' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 14.39
M-Score: -3.94
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -374.62
INO's Operating margin (%) is ranked higher than
62% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. INO: -374.62 )
INO' s 10-Year Operating margin (%) Range
Min: -8188.89   Max: -82.67
Current: -374.62

-8188.89
-82.67
Net-margin (%) -453.43
INO's Net-margin (%) is ranked higher than
62% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. INO: -453.43 )
INO' s 10-Year Net-margin (%) Range
Min: -5759.26   Max: -79.32
Current: -453.43

-5759.26
-79.32
ROE (%) -45.86
INO's ROE (%) is ranked higher than
70% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. INO: -45.86 )
INO' s 10-Year ROE (%) Range
Min: -152.12   Max: -32.52
Current: -45.86

-152.12
-32.52
ROA (%) -36.52
INO's ROA (%) is ranked higher than
69% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. INO: -36.52 )
INO' s 10-Year ROA (%) Range
Min: -98.97   Max: -25.77
Current: -36.52

-98.97
-25.77
ROC (Joel Greenblatt) (%) -1049.59
INO's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. INO: -1049.59 )
INO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7552.88   Max: -481.97
Current: -1049.59

-7552.88
-481.97
Revenue Growth (%) 6.50
INO's Revenue Growth (%) is ranked higher than
83% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. INO: 6.50 )
INO' s 10-Year Revenue Growth (%) Range
Min: -78   Max: 180.2
Current: 6.5

-78
180.2
EBITDA Growth (%) -16.80
INO's EBITDA Growth (%) is ranked higher than
67% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. INO: -16.80 )
INO' s 10-Year EBITDA Growth (%) Range
Min: -28.1   Max: 15.7
Current: -16.8

-28.1
15.7
EPS Growth (%) 28.10
INO's EPS Growth (%) is ranked higher than
92% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. INO: 28.10 )
INO' s 10-Year EPS Growth (%) Range
Min: -40.3   Max: 57.1
Current: 28.1

-40.3
57.1
» INO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

INO Guru Trades in Q4 2013

Jean-Marie Eveillard 250,000 sh (New)
Louis Moore Bacon Sold Out
» More
Q1 2014

INO Guru Trades in Q1 2014

Paul Tudor Jones 31,085 sh (New)
Jean-Marie Eveillard Sold Out
» More
Q2 2014

INO Guru Trades in Q2 2014

Paul Tudor Jones Sold Out
» More
Q3 2014

INO Guru Trades in Q3 2014

Paul Tudor Jones 12,215 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with INO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-03-31 Sold Out $9.76 - $15.28 $ 8.78-26%0
Jean-Marie Eveillard 2013-12-31 New Buy$6.92 - $11.88 $ 8.786%250000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Inovio Pharmaceuticals Inc

Inovio CEO Invests in 250,000 Shares of Company Stock
The CEO of Inovio Pharmaceuticals Inc (INO), Jong Joseph Kim, purchased 250,000 shares for $2,265,000 on August 12. The average price per share was $9.06. Read more...

Ratios

vs
industry
vs
history
P/B 4.55
INO's P/B is ranked higher than
78% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. INO: 4.55 )
INO' s 10-Year P/B Range
Min: 0.38   Max: 13.16
Current: 4.55

0.38
13.16
P/S 51.62
INO's P/S is ranked higher than
71% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. INO: 51.62 )
INO' s 10-Year P/S Range
Min: 1.57   Max: 1464
Current: 51.62

1.57
1464
EV-to-EBIT -11.82
INO's EV-to-EBIT is ranked higher than
52% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INO: -11.82 )
INO' s 10-Year EV-to-EBIT Range
Min: -32.5   Max: -0.3
Current: -11.82

-32.5
-0.3
Current Ratio 11.72
INO's Current Ratio is ranked higher than
89% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. INO: 11.72 )
INO' s 10-Year Current Ratio Range
Min: 0.82   Max: 16.04
Current: 11.72

0.82
16.04
Quick Ratio 11.72
INO's Quick Ratio is ranked higher than
90% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. INO: 11.72 )
INO' s 10-Year Quick Ratio Range
Min: 0.82   Max: 16.04
Current: 11.72

0.82
16.04

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.36
INO's Price/Net Cash is ranked higher than
87% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. INO: 6.36 )
INO' s 10-Year Price/Net Cash Range
Min: 2.25   Max: 288
Current: 6.36

2.25
288
Price/Net Current Asset Value 6.28
INO's Price/Net Current Asset Value is ranked higher than
86% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. INO: 6.28 )
INO' s 10-Year Price/Net Current Asset Value Range
Min: 2.15   Max: 288
Current: 6.28

2.15
288
Price/Tangible Book 5.22
INO's Price/Tangible Book is ranked higher than
80% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. INO: 5.22 )
INO' s 10-Year Price/Tangible Book Range
Min: 1.14   Max: 20.53
Current: 5.22

1.14
20.53
Price/Median PS Value 3.20
INO's Price/Median PS Value is ranked higher than
71% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. INO: 3.20 )
INO' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 58.82
Current: 3.2

0.24
58.82
Earnings Yield (Greenblatt) -8.50
INO's Earnings Yield (Greenblatt) is ranked higher than
70% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. INO: -8.50 )
INO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -8.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GBMB.Germany,
Inovio Biomedical Corporation was originally incorporated on June 29, 1983, under the laws of California as Biotechnologies & Experimental Research, Inc. The entity changed its corporate name to BTX, Inc. on December 10, 1991, and Genetronics, Inc. on February 8, 1994. On April 14, 1994, the board of directors approved a share exchange agreement with Consolidated United Safety Technologies Inc. On September 2, 1997, it listed on the Toronto Stock Exchange as Genetronics Biomedical Ltd, under the laws of British Columbia, Canada, which wholly owned Genetronics, Inc. On June 15, 2001, it completed a change in jurisdiction of incorporation from British Columbia, Canada, to the state of Delaware and became Genetronics Biomedical Corporation, a Delaware corporation. On January 17, 2003, Genetronics voluntarily de-listed from the Toronto Stock Exchange. On March 31, 2005, its corporate name changed from Genetronics Biomedical Corporation to Inovio Biomedical Corporation. On June 1, 2009, it completed the acquisition of VGX Pharmaceuticals, Inc. ('VGX'), a privately-held company, pursuant to the terms of an Amended and Restated Agreement and Plan of Merger dated December 5, 2008, as further amended on March 31, 2009 by and among Inovio, Inovio's wholly-owned subsidiary Inovio Acquisition, LLC and VGX (the 'Merger'). Upon the closing of the Merger, Inovio Acquisition, LLC assumed all of VGX's business, properties and assets and assumed its obligations, changed its name to VGX Pharmaceuticals, LLC, and remains a wholly-owned subsidiary of the Company, utilizing a single, integrated management team with Inovio. On May 14, 2010, the entity changed its corporate name to Inovio Pharmaceuticals, Inc. The Company is engaged in the development of a new generation of vaccines and immune therapies, called synthetic vaccines, focused on cancers and infectious diseases. Its DNA-based SynCon technology is designed to provide universal protection against known as well as new unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with its proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Its preclinical development and clinical programs include cervical dysplasia/cancer (therapeutic), influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. The Company faces competition from several development-stage and established enterprises, including major pharmaceutical and biotechnology firms, which are actively engaged in infectious disease and cancer vaccine research and development. Any pharmaceutical products that the Company develops will require regulatory clearances prior to clinical trials and additional regulatory approvals prior to commercialization. The Company's clinical programs include cervical dysplasia (therapeutic), avian influenza (pre
» More Articles for INO

Headlines

Articles On GuruFocus.com
Inovio Pharmaceuticals' CEO Dr. J. Joseph Kim Interviewed by The Life Sciences Report Oct 30 2014 
Inovio CEO Invests in 250,000 Shares of Company Stock Aug 13 2014 
comment on INO May 10 2013 
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
Weekly CFO Buys Highlight: ZBB, INO, LPR, PMC, FGP, PRMW Jun 17 2012 
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 
Any opinions regarding Apr 12 2010 

More From Other Websites
Inovio Pharmaceuticals Initiates DNA Immunotherapy Trial for Breast, Lung and Pancreatic Cancers Dec 18 2014
Nasdaq stocks posting largest percentage decreases Dec 17 2014
Inovio Pharmaceuticals Appoints Zane Yang, M.D. Vice President, Clinical Development, Oncology Dec 17 2014
8:03 am Inovio Pharma appoints Zane Yang, M.D. Vice President, Clinical Development, Oncology Dec 17 2014
Inovio Pharmaceuticals Appoints Zane Yang, M.D. Vice President, Clinical Development, Oncology Dec 17 2014
Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index Dec 15 2014
Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index Dec 15 2014
Why Inovio Pharmaceuticals (INO) Stock Might be a Great Pick Dec 05 2014
Ebola, Ethics, And The New Normal Of Scary Germs Dec 04 2014
Document for Inovio Pharmaceuticals, Inc. Nov 25 2014
Inovio Pharmaceuticals, Inc. (Nasdaq: INO) to Ring The Nasdaq Stock Market Opening Bell Nov 24 2014
Inovio Pharmaceuticals, Inc. (Nasdaq: INO) to Ring The Nasdaq Stock Market Opening Bell Nov 24 2014
Video-Revolutionizing the Fight Against Cancers and Infectious Diseases for Inovio Pharmaceuticals,... Nov 24 2014
Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market Nov 24 2014
Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market Nov 24 2014
Inovio Pharmaceuticals Melanoma DNA Immunotherapy Inhibits Tumor Growth and Increases Survival in... Nov 20 2014
Inovio-Roche End Deal for Development of Cancer Therapy Nov 18 2014
INOVIO PHARMACEUTICALS, INC. Financials Nov 18 2014
INOVIO PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement,... Nov 17 2014
Inovio Pharmaceuticals (INO) Stock Drops Following Roche Collaboration Termination Nov 17 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK